Sector
Expertise

Life
Sciences

Life Sciences

For nearly two decades, we’ve assisted pharmaceutical, biotechnology, consumer health, diagnostic, digital health, and medical device organisations in attracting and developing senior executives.

Whether you are a start-up, an established corporation, or a CMO, and working on pre-clinical or clinical development, or commercialisation, we’ll help you build collaborative teams. We are skilled in customising our approach to attract diverse, globally-experienced leaders for science-driven environments.

Contact Rosalie, Practice Lead
Graphic

Key Trends in Life Sciences

Diversity and Sustainability

Global patient demographics, emerging market demands and opportunities, and an increasingly female talent pool require inclusive leadership. Business leaders must become adept at recognising and prioritising the importance of diversity to harness its advantages for business and society.

When it comes to sustainability, we aspire to the same standards as our clients. We are proud to have been awarded a Bronze rating by Ecovadis in 2022.

1

Collaboration

New business models require collaborative approaches to pipeline innovation, manufacturing and supply, and myriad bench-to-bedside translations. This matrix of layered initiatives requires leaders at all levels of the organisation to be capable of cutting across traditional disciplines through influence, persuasion and compromise.

2

Precision and Personalised Medicine

The scientific advances that are giving rise to precision and personalised medicine are some of the great disruptors of our time. The radical changes that will emerge require leaders to be highly flexible, broad thinkers, who are comfortable challenging and ultimately dismantling the status quo.

3

Value-Driven Patient Access in a Limited Resource Healthcare Ecosystem

Long-term strategic planners who can realistically assess risk and make tough R&D decisions are needed to lead life science companies. They must provide value-driven access to a wide variety of customers and stakeholders in a healthcare ecosystem with limited resources, as well as develop innovative products and therapies. Alternative channels to market will be an inevitable component of any new strategy.

4

Diversity and Sustainability

Global patient demographics, emerging market demands and opportunities, and an increasingly female talent pool require inclusive leadership. Business leaders must become adept at recognising and prioritising the importance of diversity to harness its advantages for business and society.

When it comes to sustainability, we aspire to the same standards as our clients. We are proud to have been awarded a Bronze rating by Ecovadis in 2022.

5

Big Data, Digitalization, and Artificial Intelligence

Big data collection and usage; digitalization; and artificial intelligence in the entire life-cycle of therapies, from development to the point of patient access, are unstoppable trends. Wielding these technology tools in a meaningful way requires innovation leadership that is balanced by well-defined change management skills and a keen ability to prioritise.

Latest News in Life Sciences

August 7, 2022

Amid Wegovy’s supply woes, Novo Nordisk sees surging demand for its original obesity drug Saxenda

Life sciences

After a contract manufacturing snafu in December, supply of Novo Nordisk’s GLP-1 med for obesity appears to be back on track in the U.S.—mostly. Novo’s Wegovy manufacturing partner—which the Danish company previously confirmed to Fierce Pharma as Catalent—restarted production on the med in 2022’s second quarter. As a result, 1.7-mg and 2.4-mg doses of Wegovy are back on tap in the U.S. market, Novo said in a recent investor report.

August 7, 2022

After delay, CSL’s $11.7B deal for Vifor poised to close next week

Life sciences

Once the offer is settled, CSL expects to get its hands on more than 97% of Vifor shares. At the same time, CSL plans to have Vifor apply for the delisting of its shares post-close. CSL has also filed an action to cancel remaining publicly held Vifor shares to satisfy Swiss takeover rules.

August 7, 2022

Amgen to acquire biopharma firm ChemoCentryx for $3.7bn

Life sciences

Amgen has signed a definitive agreement to acquire biopharmaceutical company ChemoCentryx for $52 for each share in cash or a total enterprise cost of nearly $3.7bn. ChemoCentryx focuses on orally administered therapeutics for the treatment of inflammatory disorders, autoimmune ailments and cancer.

Subscribe to our Weekly Newsletter

Understanding your business is our business